Survival With and Without Liver Transplantation in Critically Ill Patients With Cirrhosis: A 20-Year Experience.

IF 12 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
William Bernal, Therese Bittermann, Roosey Sheth, Francesca Trovato, Mark J McPhail, Pervez Khan, Stacey Calvert, Tasneem Pirani, Sameer Patel, Robert Loveridge, Christopher Willars, Georg Auzinger, Julia A Wendon
{"title":"Survival With and Without Liver Transplantation in Critically Ill Patients With Cirrhosis: A 20-Year Experience.","authors":"William Bernal, Therese Bittermann, Roosey Sheth, Francesca Trovato, Mark J McPhail, Pervez Khan, Stacey Calvert, Tasneem Pirani, Sameer Patel, Robert Loveridge, Christopher Willars, Georg Auzinger, Julia A Wendon","doi":"10.1016/j.cgh.2025.04.029","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>In 2015, we reported the outcome of patients with cirrhotic chronic liver disease with unplanned admission to a specialist single-center Liver Intensive Therapy Unit (LITU) demonstrating progressive improvement in short-term survival. We investigated if this and long-term survival had continued to improve, and its relation to use and outcome of liver transplantation (LT).</p><p><strong>Methods: </strong>A retrospective cohort study of consecutive adult patients with cirrhosis and unplanned emergent first LITU admission January 2000 to March 2020. Demographic and clinical variables were obtained at admission; acute-on-chronic liver failure (ACLF) grade was categorized as 0 (no ACLF), 1 or 2, or 3. Transplant-free survival (TFS) and LT practices were characterized and survival compared using time-to-event analysis.</p><p><strong>Results: </strong>The cohort comprised 1688 patients (62% male; median age 52 years [interquartile range, 43-60 years]) with Model for End-Stage Liver Disease score 28 (interquartile range, 18-37); 23% had no ACLF, 39% had ACLF 1 or 2, and 37% had ACLF 3; TFS closely related to ACLF grade (P < .001). LITU TFS was 51.9% in 2000 to 2009, increasing to 70.6% in 2010 to 2020 (P < .001); improvement for ACLF 3 was smaller: 31.0% to 45.8%, (P < .001). There was no difference in TFS survival in 2010 to 2014 vs 2015 to 2020. Long-term TFS was poor with <20% of patients alive without LT 1 year after LITU admission. During follow-up, 280 underwent LT: the proportion transplanted increased from 12.6% in 2000 to 2009 to 20.2% in 2010 to 2020, with 1- and 5-year post-transplant survival of 91% and 81.9%.</p><p><strong>Conclusions: </strong>TFS has now plateaued with need for novel interventions to improve survival in ACLF. LT is infrequently utilized but has excellent outcomes. ACLF survivors should be closely followed up with strong consideration given for transplant assessment.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cgh.2025.04.029","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & aims: In 2015, we reported the outcome of patients with cirrhotic chronic liver disease with unplanned admission to a specialist single-center Liver Intensive Therapy Unit (LITU) demonstrating progressive improvement in short-term survival. We investigated if this and long-term survival had continued to improve, and its relation to use and outcome of liver transplantation (LT).

Methods: A retrospective cohort study of consecutive adult patients with cirrhosis and unplanned emergent first LITU admission January 2000 to March 2020. Demographic and clinical variables were obtained at admission; acute-on-chronic liver failure (ACLF) grade was categorized as 0 (no ACLF), 1 or 2, or 3. Transplant-free survival (TFS) and LT practices were characterized and survival compared using time-to-event analysis.

Results: The cohort comprised 1688 patients (62% male; median age 52 years [interquartile range, 43-60 years]) with Model for End-Stage Liver Disease score 28 (interquartile range, 18-37); 23% had no ACLF, 39% had ACLF 1 or 2, and 37% had ACLF 3; TFS closely related to ACLF grade (P < .001). LITU TFS was 51.9% in 2000 to 2009, increasing to 70.6% in 2010 to 2020 (P < .001); improvement for ACLF 3 was smaller: 31.0% to 45.8%, (P < .001). There was no difference in TFS survival in 2010 to 2014 vs 2015 to 2020. Long-term TFS was poor with <20% of patients alive without LT 1 year after LITU admission. During follow-up, 280 underwent LT: the proportion transplanted increased from 12.6% in 2000 to 2009 to 20.2% in 2010 to 2020, with 1- and 5-year post-transplant survival of 91% and 81.9%.

Conclusions: TFS has now plateaued with need for novel interventions to improve survival in ACLF. LT is infrequently utilized but has excellent outcomes. ACLF survivors should be closely followed up with strong consideration given for transplant assessment.

肝硬化危重患者肝移植和不肝移植的生存:20年的经验。
背景与目的:2015年,我们报道了计划外入住专科单中心肝脏强化治疗病房(LITU)的肝硬化慢性肝病(CLD)患者的结果,显示其短期生存率渐进式改善。我们调查了这个和长期生存率是否持续改善,以及它与肝移植(LT)的使用和结果的关系。方法:回顾性队列研究2000年1月1日至2020年3月1日连续入院的成年肝硬化非计划紧急首次LITU患者。入院时获得人口学和临床变量;ACLF分级分为0级(无ACLF)、1-2级和3级。无移植生存(TFS)和移植实践的特征和生存比较使用时间-事件分析。结果:该队列包括1,688例患者,62%为男性,中位年龄52岁(IQR 43-60), MELD评分28 (18-37);无ACLF者23%,ACLF-1-2者39%,ACLF-3者37%;结论:由于需要新的干预措施来提高ACLF患者的生存率,TFS现已达到平台期。肝移植虽不常用,但疗效良好。ACLF幸存者应密切随访,并强烈考虑移植评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
16.90
自引率
4.80%
发文量
903
审稿时长
22 days
期刊介绍: Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信